Pfizer Ltd (PFIZER)
₹4,581.60
Mkt cap
₹21,088 Cr
P/E ratio
27.40
P/B
4.99
Div yield
1.63%
ROE
18.00%
ROCE
24.10%
EPS (TTM)
₹167.21
Book value
₹919
52W range
4,405–5,530
Sector
Healthcare
Price history
Previous close
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. [1] It is the 3rd largest multinational pharmaceutical company in India. [2]
NSE PFIZERBSE 500680
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−17.14% from high₹4,582
₹4,405+4.01% from low₹5,530
Current
₹4,581.60
Prev close
₹4,600.00
Day
−0.40%
Price performance
1D
−0.40%
1W
−2.19%
1M
−6.13%
3M
−0.24%
6M
−5.85%
1Y
−10.78%
YTD
−6.25%
Financials
Revenue, profit & margin
P/E ratio
27.4×
PFIZER is 19% below the sector median of 34.0×
PFIZER27.4×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 | |
| Expenses | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 406 | |
| Operating Profit | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 | 248 | |
| OPM % | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% | 38% | |
| Other Income | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 | 45 | |
| Interest | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 1 | |
| Depreciation | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 | 14 | |
| Profit before tax | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 | |
| Tax % | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% | 26% | |
| Net Profit | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 | |
| EPS in Rs | 20.44 | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.00 | 43.68 | 44.70 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.06% · closed higher next day 19 of last 55
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 28 Oct '23◦ | 9 Feb '24◦ | 17 May '24◦ | 29 Jul '24◦ | 28 Oct '24◦ | 31 Jan '25◦ | 20 May '25◦ | 13 Aug '25◦ | 12 Nov '25◦ | 9 Feb '26◦ | 12 May '26◦ | 28 Jul '26 |
| Earnings day | +0.19% | −0.00% | +1.65% | +3.99% | −1.37% | +0.54% | +0.59% | +4.33% | +0.56% | +4.13% | −2.38% | +0.94% |
| +1 day | −0.05% | −0.73% | −0.41% | +5.27% | −3.25% | −0.75% | +3.83% | +12.91% | +1.17% | +9.10% | −0.95% | +1.92% |
| +5 days | −0.61% | +5.61% | +3.43% | +7.92% | +0.96% | −3.97% | +11.34% | +10.99% | +0.26% | +6.06% | −0.81% | +4.19% |
| +15 days | +2.53% | +5.30% | +11.99% | +11.32% | −0.81% | −9.76% | +16.69% | +0.71% | −0.29% | +2.15% | −6.42% | +4.43% |
| +30 days | +4.09% | −3.59% | +4.08% | +14.01% | −4.64% | −10.18% | +15.46% | −3.95% | +0.73% | −1.15% | −5.61% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 75 Per Share | 75.00 | 17 Jul '26 | 17 Jul '26 |
Shareholding
as of Jun 202663.92%Promoter
Promoters63.92%
FIIs1.65%1.16
DIIs17.80%0.91
Public16.62%0.26
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| PFIZER | ₹4,609.70 | 27.42 | 21,088 | 1.63% | 204 | +6.63% | 653 | +8.31% | 24.06% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts7
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Aug - Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 29 JulShareholder Meeting / Postal Ballot-Outcome of AGM 28 Jul - Pfizer held its 75th AGM on July 28, 2026, and declared Rs.75 per share dividend.Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30, 2026. 28 Jul - Pfizer approved Q1 FY2026-27 unaudited results; net profit rose to ₹204.47 crore.Announcement under Regulation 30 (LODR)-Change in Directorate 27 Jul - Mr. Amit Agarwal resigns as Executive Director-Finance and CFO effective October 8, 2026.